Predictors of complications occurring after open and robot-assisted prostate cancer surgery: a retrospective evaluation of 1062 consecutive patients treated in a tertiary referral high volume center.


Journal

Journal of robotic surgery
ISSN: 1863-2491
Titre abrégé: J Robot Surg
Pays: England
ID NLM: 101300401

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 30 11 2020
accepted: 15 01 2021
pubmed: 10 2 2021
medline: 25 2 2022
entrez: 9 2 2021
Statut: ppublish

Résumé

To investigate factors associated with the risk of major complications after radical prostatectomy (RP) by the open (ORP) or robot-assisted (RARP) approach for prostate cancer (PCa) in a tertiary referral center. 1062 consecutive patients submitted to RP were prospectively collected. The following outcomes were addressed: (1) overall postoperative complications: subjects with Clavien-Dindo System (CD) one through five versus cases without any complication; (2) moderate to major postoperative complications: cases with CD < 2 vs.  ≥ 2, and 3) major post-operative complications: subjects with CDS CD ≥  3 vs.  < 3. The association of pre-operative and intra-operative factors with the risk of postoperative complications was assessed by the logistic regression model. Overall, complications occurred in 310 out of 1062 subjects (29.2%). Major complications occurred in 58 cases (5.5%). On multivariate analysis, major complications were predicted by PCa surgery and intraoperative estimated blood loss (EBL). ORP compared to RARP increased the risk of major CD complications from 2.8 to 19.3% (OR = 8283; p < 0.0001). Performing ePLND increased the risk of major complications from 2.4 to 7.4% (OR = 3090; p < 0.0001). Assessing intraoperative blood loss, the risk of major postoperative complications was increased by BL above the third quartile when compared to subjects with intraoperative blood loss up to the third quartile (10.2% vs. 4.6%; OR = 2239; 95%CI: 1233-4064). In the present cohort, radical prostatectomy showed major postoperative complications that were independently predicted by the open approach, extended lymph-node dissection, and excessive intraoperative blood loss.

Identifiants

pubmed: 33559802
doi: 10.1007/s11701-021-01192-w
pii: 10.1007/s11701-021-01192-w
pmc: PMC8863696
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-52

Informations de copyright

© 2021. The Author(s).

Références

Br J Urol. 1996 Aug;78(2):161-8
pubmed: 8813905
Minerva Urol Nefrol. 2020 Feb;72(1):72-81
pubmed: 31833722
Tumori. 2018 Mar-Apr;104(2):111-115
pubmed: 27791231
BJU Int. 2008 May;101(9):1145-9
pubmed: 18399830
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Asian J Androl. 2020 May-Jun;22(3):323-329
pubmed: 31347517
J Endourol. 2017 Sep;31(9):864-871
pubmed: 28853623
Tumori. 2017 May 12;103(3):299-306
pubmed: 27716882
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Minerva Urol Nefrol. 2019 Apr;71(2):136-145
pubmed: 30767495
BJU Int. 2018 Nov;122(5):801-807
pubmed: 29727912
Clin Genitourin Cancer. 2017 Feb;15(1):67-71
pubmed: 27452733
Scand J Urol. 2019 Feb;53(1):26-33
pubmed: 30727795
J Urol. 1998 Dec;160(6 Pt 2):2418-24
pubmed: 9817395
Prostate. 2020 Feb;80(2):153-161
pubmed: 31746484
Eur Urol. 2012 Sep;62(3):368-81
pubmed: 22763081
Asian J Urol. 2016 Apr;3(2):88-95
pubmed: 29264170
BJU Int. 2013 May;111(5):753-60
pubmed: 23464824
Urol Oncol. 2016 Jun;34(6):255.e1-5
pubmed: 26935867
Urology. 2020 May;139:71-77
pubmed: 32084413
Urol Int. 2017;98(1):32-39
pubmed: 27798942
Lancet. 2016 Sep 10;388(10049):1057-1066
pubmed: 27474375
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
BJU Int. 2021 Mar;127(3):318-325
pubmed: 32869940
J Robot Surg. 2015 Sep;9(3):249-55
pubmed: 26531206
Urol Int. 2016;97(1):32-41
pubmed: 26998904
Eur Urol. 2009 Dec;56(6):972-80
pubmed: 19781848
Urol Int. 2019;103(1):25-32
pubmed: 31067558
J Robot Surg. 2019 Feb;13(1):83-89
pubmed: 29737495
Actas Urol Esp. 2013 Jan;37(1):1-11
pubmed: 22824080
J Urol. 2003 Jun;169(6):2289-92
pubmed: 12771773
J Endourol. 2021 Jun;35(6):922-928
pubmed: 30398382

Auteurs

Antonio Benito Porcaro (AB)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy. drporcaro@yahoo.com.

Alessandro Tafuri (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy. alessandro.tafuri@univr.it.
Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chieti-Pescara, Italy. alessandro.tafuri@univr.it.

Riccardo Rizzetto (R)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Nelia Amigoni (N)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Marco Sebben (M)

Sacro Cuore Don Calabria Hospital, IRCCS, Negrar, Italy.

Aliasger Shakir (A)

USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA.

Katia Odorizzi (K)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Alessandra Gozzo (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Sebastian Gallina (S)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Alberto Bianchi (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Paola Irene Ornaghi (PI)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Stefano Zecchini Antoniolli (SZ)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Vincenzo Lacola (V)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Matteo Brunelli (M)

Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Filippo Migliorini (F)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Maria Angela Cerruto (MA)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Salvatore Siracusano (S)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Walter Artibani (W)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Alessandro Antonelli (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH